Details for Patent: 9,174,982
✉ Email this page to a colleague
Title: | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
Abstract: | Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. |
Inventor(s): | Bruncko; Milan (Green Oaks, IL), Ding; Hong (Gurnee, IL), Doherty; George A. (Libertyville, IL), Elmore; Steven W. (Northbrook, IL), Hasvold; Lisa A. (Grayslake, IL), Hexamer; Laura (Grayslake, IL), Kunzer; Aaron R. (Schaumburg, IL), Song; Xiaohong (Grayslake, IL), Souers; Andrew J. (Evanston, IL), Sullivan; Gerard M. (Lake Villa, IL), Tao; Zhi-Fu (Gurnee, IL), Wang; Gary T. (Libertyville, IL), Wang; Le (Vernon Hills, IL), Wang; Xilu (Grayslake, IL), Wendt; Michael D. (Vernon Hills, IL), Mantei; Robert A. (Franklin, WI), Hansen; Todd M. (Grayslake, IL) |
Assignee: | ABBVIE INC. (North Chicago, IL) GENENTECH, INC. (South San Francisco, CA) THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (Parkville, AU) |
Filing Date: | Sep 26, 2013 |
Application Number: | 14/038,304 |
Claims: | 1. A method of treating a cancer selected from the group consisting of chronic lymphocytic leukemia, lymphoblastic leukemia, follicular lymphoma, a lymphoid malignancy of T cell or B cell origin, myelogenous leukemia, myeloma and breast cancer in a patient, said method comprising administering to the patient a therapeutically effective amount of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin- -1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfony- l)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the cancer is chronic lymphocytic leukemia. 3. The method of claim 1, wherein the cancer is lymphoblastic leukemia. 4. A method of treating chronic lymphocytic leukemia in a patient, said method comprising administering to the patient a therapeutically effective amount of a compound 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin- -1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfony- l)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide. 5. A method of treating lymphoblastic leukemia in a patient, said method comprising administering to the patient a therapeutically effective amount of a compound 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin- -1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfony- l)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide. 6. A method of treating myeloma in a patient, said method comprising administering to the patient a therapeutically effective amount of a compound 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}- piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pheny- l}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide. 7. A method of treating breast cancer in a patient, said method comprising administering to the patient a therapeutically effective amount of a compound 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin- -1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfony- l)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide. |